XDemics Corporation Receives U.S. Patent for Core Cell Culture Technology
Patent Provides Broad Protection for the Company’s Expansify™ Platform Under Exclusive License from California Institute of Technology and City of Hope National Medical Center
SAN RAFAEL, Calif., (April 21, 2026) -- XDemics Corporation, a Caltech spin-out developing next- generation cultureware and bioreactor systems for biomedical research and therapeutic manufacturing, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,606,784. The issued claims provide broad intellectual property protection covering the foundational technology behind the company’s Expansify™ cultureware platform. The patent issued on April 21, 2026.
XDemics holds an exclusive worldwide license to the patent from the California Institute of Technology (Caltech) and City of Hope National Medical Center, the co-owners of the underlying invention. The newly issued patent strengthens the company’s competitive position as it enters commercialization of its High-Density Cell Respiration™ (HDCR™) product line.
“The issuance of this patent is a significant milestone for XDemics,” said Christopher Thanos, CEO. “It validates the novelty of the core technology that underpins our Expansify™ platform and reinforces our intellectual property portfolio as we scale commercial production. The breadth of the issued claims reflects years of foundational research at Caltech and City of Hope, and we are proud to bring this innovation to market.”
The technology addresses a fundamental limitation in conventional cell culture: the inability to efficiently deliver oxygen to growing cells at scale. By decoupling gas exchange from nutrient delivery through a novel gas-permeable membrane architecture, the Expansify™ platform enables mammalian cells to reach densities up to 100 times higher than those achieved in standard polystyrene cultureware in a shear-stress free, high-quality manner. Furthermore, Expansify™ enables tunable, pericellular oxygenation across the full physiological range. The result is dramatically improved product quality, yield, reduced processing time, and lower manufacturing costs across a range of applications, from early-stage research to commercial-scale production of cell and gene therapies.
About XDemics
XDemics Corporation is developing the High-Density Cell Respiration (HDCR™) platform to overcome the oxygen delivery and shear stress limitations of conventional cell culture systems, enabling direct control of pericellular oxygen at any setpoint and achieving up to 100-fold higher cell densities with improved product potency and quality. The company's Expansify™ respiring cultureware and Profusion™ bioreactor products (under development) utilize HDCR™ to enable predictable, linear scaleup from 96- well plates to large bioreactors, supporting workflows from early discovery to commercial production of T cell, stem cell, and viral-based therapies. XDemics holds an exclusive license to a broad IP portfolio from Caltech and City of Hope, complemented by significant IP generated in-house. The company is headquartered in San Rafael, California.
Expansify™ cultureware is currently for research use only.
How to reach us:
- For more information, please visit www.xdemics.com
- General inquiries, please email: info@xdemics.com
- Technical support or questions, please email: support@xdemics.com